Clinical Trial Update: A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy [Phase 3]

View source ↗

Summary

Update on a Phase 3 non-inferiority trial comparing DOR/3TC/TDF to DTG/TAF/FTC as first-line antiretroviral therapy in people with HIV-1 infection; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• DOR/3TC/TDF (doravirine/lamivudine/tenofovir disoproxil fumarate)
• DTG/TAF/FTC (dolutegravir/tenofovir alafenamide/emtricitabine)

Snippet

Sponsor: Professor Francois Venter | Conditions: HIV-1-infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING